Medication leaflets

Active substance

Results for the substance secukinumab

5 results

About this active substance

Secukinumab is a biologic medication used to treat autoimmune inflammatory diseases such as moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is a human monoclonal antibody that works by inhibiting interleukin-17A (IL-17A), a cytokine involved in inflammatory and autoimmune processes.

By blocking IL-17A, secukinumab reduces inflammation and symptoms associated with these conditions, such as joint pain, stiffness, and skin lesions. It is administered as a subcutaneous injection according to a schedule determined by a healthcare provider.

Common side effects include upper respiratory tract infections, diarrhea, headaches, and injection site reactions. In rare cases, it may increase the risk of severe infections or trigger inflammatory bowel disease.

Patients should inform their doctor about any other medical conditions or medications before starting secukinumab. Regular monitoring is essential to assess the treatment's effectiveness and safety.